C7287

Canrenoic acid potassium salt

powder

• Synonym(s): 17-Hydroxy-3-oxopregna-4,6-diene-21-carboxylic acid, Potassium canrenoate
• Linear Formula: C₂₂H₃₀O₄K
• CAS Number: 2181-04-6
• Molecular Weight: 397.57
• EC Number: 218-554-9
• MDL number: MFCD05662375
• UNSPSC Code: 12352106
• PubChem Substance ID: 24892953
• NACRES: NA.77

Properties

• form: powder
• color: light yellow to tan
• SMILES string: [K].[H][C@]12CC[C@@]3(C)[C@@]([H])(CC[C@@]3(O)CCC(O)=O)[C@]1([H])C=CC4=CC(=O)CC[C@]24C
• InChI: 1S/C22H30O4.K.H/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25;;/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25);;/t16-,17+,18+,20+,21+,22-;;/m1../s1
• InChI key: YLXFIHIYNGPPSF-HUHWECDNSA-N

Description

Application

Canrenoic acid potassium salt has been used as a human uridine 5′-diphospho (UDP)-glucuronosyltransferase inhibitor to study its effects on trifluoperazine (TFP) substrate selectivity. It has also been used to study its effects on the formation of aldosterone 18-glucuronide (ALDO 18β-G) in recombinant UDP-Glucuronosyltransferase-2B7 (UGT2B7), human liver (HLM) and human kidney cortical (HKCM) microsomes.

Biochem/physiol Actions

Competitive aldosterone receptor antagonist. Potassium canrenoate reduces the effects of aldosterone-induced increases in blood pressure and in cardiovascular fibrosis in animals with high sodium intake. It is used clinically for its anti-fibrotic effects. At higher doses it is genotoxic to liver and increases tumor incidence in rodent models.

Quality

Aqueous solutions may contain some insoluble material.

Safety Information

• Pictograms: GHS07
• Signal Word: Warning
• Hazard Statements: H302
• Hazard Classifications: Acute Tox. 4 Oral
• Storage Class Code: 11 - Combustible Solids
• WGK: WGK 3
• Personal Protective Equipment: dust mask type N95 (US), Eyeshields, Gloves